How could Myfortic® fulfil the needs for graft protection in your transplant patients?
1. Improving GI tolerability after switching from MMF1
Approximately 66% of patients and 78% of physicians reported an improvement in GI tolerability after switching to Myfortic®1
Overall treatment effect scores after switching to Myfortic® for patient-rated and physician-rated GI symptoms (n=177)1
2. Reducing dose reductions and discontinuations compared to MMF2
% of patients requiring dose reduction by 2 years2
% of patients requiring drug discontinuation by 2 years2
3. Enabling increased MPA capacity while reducing GI complications when transitioned from MMF3
Patients who tolerated intermediate MPA doses at 12 weeks
Patients reporting at least one GI AE
4. Lowering incidence of acute kidney rejection and BPAR vs MMF2
% of patients for outcome variables at 2 years2
Study designs
1A multicenter, open-label, prospective study was undertaken in MMF-treated renal transplant patients including patients experiencing GI complaints were converted to equimolar EC-MPS (Cohort A, n=177) and patients without GI complaints remained on MMF (Cohort B, n=101), to determine if patients with GI complaints who are converted from MMF to EC-MPS experience improvements in GI symptom severity and HRQoL; and to evaluate the impact of GI symptoms on patients’ perceptions of symptom severity, GI-specific HRQoL, and general HRQoL.
2A retrospective study comparing MMF and EC-MPS in all consecutive kidney transplants (n=1,709) between 2000 and 2006 was conducted to determine whether there was a clinically significant difference in dose alterations and outcomes with EC-MPS compared with MMF.
3The present randomized, multicenter, open-labeled, 12-week study included renal transplant recipients experiencing GI adverse events due to MMF treatment. Patients were randomized to continue with MMF (n=54) or change to EC-MPS (n=59). Patients were converted at equimolar doses, and dose was optimized between weeks 2 and 6 to achieve maximum tolerated dose.
Abbreviations:
GI: gastrointestinal; MMF: mycophenolate mofetil; MPA: mycophenolic acid; BPAR: biopsy-proven acute rejection
References:
1. Chan L, et al. Transplantation. 2006;81(9):1290-1297. 2. Sollinger HW, et al. Transplantation. 2010;89(4):446-451. 3. Ortega F, et al. Transplatation. 2011;92:426-432.
20 Pasir Panjang Road #10-25/28 Mapletree Business City (West Tower) Singapore 117439
Phone: +65 6722 6010
This content is not for local distribution. This should be modified to accommodate local guidance before local distribution.
FOR HEALTHCARE PROFESSIONALS ONLY
Please visit https://www.novartis.com/sg-en/product-list/myfortic to access or download the Package Insert.
Alternatively, please scan this code for more Information about this medicine.
FA-11458393_2027Jul22